Accredo
Privacy |  HIPAA |  Terms of use |  Medco |  Contact us
   
Patients Healthcare professionals Health plans & payor clients Manufacturers Careers About Accredo
 
 
 

Patients

Getting started with Accredo
Our services
Search drug therapies
Therapy management
Synagis® (palivizumab) - overview

Synagis® (palivizumab)

Overview | Product information | Accredo services | Contact team


Respiratory syncytial virus, or RSV, is a very common virus. It infects half of all children during their first year of life and, by age five, all children will have been infected at least once.(1–3) Respiratory infections caused by RSV are most common during the winter months. While most infections are mild, RSV can cause severe illness in infants who were born prematurely or who have lung problems. Up to half of these infants who become infected need to be hospitalized for breathing difficulty. Some infants get sicker than others because premature infants and infants with serious lung conditions have underdeveloped respiratory and immune systems that are less able to fight infections.

Referral Form - NC

Referral Form - All Other States

Other Resources:

American Academy of Pediatrics

Centers for Disease Control & Prevention

MedImmune

RSVProtection.com

1. Hall CB. Respiratory syncytial virus. What we now know. Contemp Pediatr. 1993;2–11.

2. Glezen WP, Taber LH, Frank AL, Kasel JA. Risk of primary infection and re-infection with respiratory syncytial virus. Am J Dis Child. 1986;140:543–546.

3. Institute of Medicine Committee on Issues and Priorities for New Vaccine Development. Prospects for immunizing against respiratory syncytial virus. In: New Vaccine Development. Establishing Priorities. Washington, D.C.: National Academy of Sciences Press; 1988;1:397–409.


Synagis is a registered trademark of MedImmune, Inc.

 
 
 

Quick links

Search Search drug therapies
Doctor Referral Doctor referral forms
Patient Authorization Patient authorization form
Contact Us Contact us